Literature DB >> 19134448

Breast cancer and the immune system.

Leanna J Standish1, Erin S Sweet, Jeffrey Novack, Cynthia A Wenner, Carly Bridge, Ana Nelson, Mark Martzen, Carolyn Torkelson.   

Abstract

This article reviews the evidence that the functioning of both the innate and the adaptive immune system plays a role in preventing relapse in women with breast cancer. Lymphocytes, including T cells, T regulatory cells, and natural killer cells, and their cytokine release patterns are implicated in both primary prevention and recurrence of breast cancer. Cancer prognosis may be related to immune system functional status. The hypothesis that the immune system has a causal role in breast cancer etiology is supported by epidemiologic, preclinical, and clinical research. Empirical support for the concept that immune status and immunomodulatory therapy have important roles in comprehensive breast cancer treatment is provided.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19134448      PMCID： PMC2845458     

Source DB:  PubMed          Journal:  J Soc Integr Oncol        ISSN： 1715-894X


  106 in total

1.  Proinflammatory CD4+ CD45RB(hi) lymphocytes promote mammary and intestinal carcinogenesis in Apc(Min/+) mice.

Authors:  Varada P Rao; Theofilos Poutahidis; Zhongming Ge; Prashant R Nambiar; Bruce H Horwitz; James G Fox; Susan E Erdman
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

Review 2.  Breast cancer in women with HIV/AIDS: report of five cases with a review of the literature.

Authors:  Soji F Oluwole; Ayoola O Ali; Zahra Shafaee; Hector A DePaz
Journal:  J Surg Oncol       Date:  2005-01-01       Impact factor: 3.454

3.  Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.

Authors:  Claudio Praga; Jonas Bergh; Judith Bliss; Jacques Bonneterre; Bruno Cesana; R Charles Coombes; Pierre Fargeot; Annika Folin; Pierre Fumoleau; Rosa Giuliani; Pierre Kerbrat; Michel Hery; Jonas Nilsson; Francesco Onida; Martine Piccart; Lois Shepherd; Patrick Therasse; Jacques Wils; David Rogers
Journal:  J Clin Oncol       Date:  2005-06-20       Impact factor: 44.544

4.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.

Authors:  Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine
Journal:  J Natl Cancer Inst       Date:  2005-07-06       Impact factor: 13.506

5.  Secondary hematological malignancies after breast cancer chemotherapy.

Authors:  Myung Joon Park; Yeon Hee Park; Heui June Ahn; Won Choi; Kwang Hyun Paik; Jung Min Kim; Yoon Hwan Chang; Baek-Yeol Ryoo; Sung Hyun Yang
Journal:  Leuk Lymphoma       Date:  2005-08

6.  Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer.

Authors:  Uri Einav; Yuval Tabach; Gad Getz; Assif Yitzhaky; Ugur Ozbek; Ninette Amariglio; Shai Izraeli; Gideon Rechavi; Eytan Domany
Journal:  Oncogene       Date:  2005-09-22       Impact factor: 9.867

7.  Racial inequities in the timing of breast cancer detection, diagnosis, and initiation of treatment.

Authors:  Joann G Elmore; Connie Y Nakano; Hannah M Linden; Lisa M Reisch; John Z Ayanian; Eric B Larson
Journal:  Med Care       Date:  2005-02       Impact factor: 2.983

8.  Immune dysfunction and micrometastases in women with breast cancer.

Authors:  Michael J Campbell; Janet Scott; Holden T Maecker; John W Park; Laura J Esserman
Journal:  Breast Cancer Res Treat       Date:  2005-05       Impact factor: 4.872

9.  Disparities and survival among breast cancer patients.

Authors:  Terry S Field; Diana S M Buist; Chyke Doubeni; Shelley Enger; Hassan Fouayzi; Gene Hart; Eli J Korner; Lois Lamerato; Donald J Bachman; Jennifer Ellis; Lisa Herrinton; Mark C Hornbrook; Rick Krajenta; Liyan Liu; Janice Yao
Journal:  J Natl Cancer Inst Monogr       Date:  2005

10.  Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

Authors:  L Arnould; M Gelly; F Penault-Llorca; L Benoit; F Bonnetain; C Migeon; V Cabaret; V Fermeaux; P Bertheau; J Garnier; J-F Jeannin; B Coudert
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640
View more
  46 in total

1.  NHERF1/EBP50 in Breast Cancer: Clinical Perspectives.

Authors:  Antonia Bellizzi; Andrea Malfettone; Rosa A Cardone; Anita Mangia
Journal:  Breast Care (Basel)       Date:  2010-04-09       Impact factor: 2.860

2.  Genetically determined inflammatory-response related cytokine and chemokine transcript profiles between mammary carcinoma resistant and susceptible rat strains.

Authors:  Bharat Devapatla; Jennifer Sanders; David J Samuelson
Journal:  Cytokine       Date:  2012-05-18       Impact factor: 3.861

3.  A Hierarchy of Healing: Origins of the Therapeutic Order and Implications for Research.

Authors:  John S Finnell; Pamela Snider; Stephen P Myers; Jared Zeff
Journal:  Integr Med (Encinitas)       Date:  2019-06

4.  Activation of regulatory T cells instigates functional down-regulation of cytotoxic T lymphocytes in human breast cancer.

Authors:  Chao-Hsu Li; Wen-Hong Kuo; Wen-Chun Chang; Su-Cheng Huang; King-Jen Chang; Bor-Ching Sheu
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

5.  Association of serum interleukin-10, interleukin-17A and transforming growth factor-α levels with human benign and malignant breast diseases.

Authors:  Zhuangwei Lv; Min Liu; Jinghui Shen; Dong Xiang; Yunfeng Ma; Yanhong Ji
Journal:  Exp Ther Med       Date:  2018-04-30       Impact factor: 2.447

Review 6.  Immune system: a double-edged sword in cancer.

Authors:  Bodduluru Lakshmi Narendra; Kasala Eshvendar Reddy; Saladi Shantikumar; Sistla Ramakrishna
Journal:  Inflamm Res       Date:  2013-07-19       Impact factor: 4.575

7.  Lymphoma risk in systemic lupus: effects of disease activity versus treatment.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Lawrence Joseph; Jean-Francois Boivin; Karen H Costenbader; Murray B Urowitz; Dafna D Gladman; Paul R Fortin; Ola Nived; Michelle A Petri; Soren Jacobsen; Susan Manzi; Ellen M Ginzler; David Isenberg; Anisur Rahman; Caroline Gordon; Guillermo Ruiz-Irastorza; Edward Yelin; Sang-Cheol Bae; Daniel J Wallace; Christine A Peschken; Mary Anne Dooley; Steven M Edworthy; Cynthia Aranow; Diane L Kamen; Juanita Romero-Diaz; Anca Askanase; Torsten Witte; Susan G Barr; Lindsey A Criswell; Gunnar K Sturfelt; Irene Blanco; Candace H Feldman; Lene Dreyer; Neha M Patel; Yvan St Pierre; Ann E Clarke
Journal:  Ann Rheum Dis       Date:  2013-01-08       Impact factor: 19.103

8.  TGF-β polymorphism and its expression correlated with CXCR4 expression in human breast cancer.

Authors:  Julie Massayo Maeda Oda; Karen Brajão de Oliveira; Roberta Losi Guembarovski; Kalil William Alves de Lima; Ana Cristina da Silva do Amaral Herrera; Alda Losi Guembarovski; Walter Jorge Sobrinho; Daniela Rudgeri Derossi; Maria Angelica Ehara Watanabe
Journal:  Mol Biol Rep       Date:  2012-09-02       Impact factor: 2.316

9.  Serum IgA1 shows increased levels of α2,6-linked sialic acid in breast cancer.

Authors:  Hannah J Lomax-Browne; Claire Robertson; Aristotelis Antonopoulos; Anthony J C Leathem; Stuart M Haslam; Anne Dell; Miriam V Dwek
Journal:  Interface Focus       Date:  2019-02-15       Impact factor: 3.906

Review 10.  Review of 10 years of research on breast cancer patients: Focus on indoleamine 2,3-dioxygenase.

Authors:  Kashif Asghar; Asim Farooq; Bilal Zulfiqar; Asif Loya
Journal:  World J Clin Oncol       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.